Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of intravenous vedolizumab in Japanese patients with moderate to severe ulcerative colitis
jRCT2080222353Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in autoimmune colitis (6 arms), sponsored by Takeda. Primary endpoint: Primary Outcome Measures. Started Dec 2013; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080222353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222353.